IPSC
Century Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.86
−1.06%0
Insider buys (3m)
5
Insider sells (3m)
-$10.4K
Net value (3m)
-20.6%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Pfeiffenberger Brent · director, officer: President and CEO | F-InKind | 13,850 | $1.94 |
| Sep 15, 2026 | Russotti Gregory · officer: See Remarks | Sale | 2,587 | $1.93 |
| Sep 15, 2026 | Carr Douglas · officer: SVP Finance & Operations | Sale | 1,658 | $1.93 |
| Sep 10, 2026 | Truitt Joseph · director | A-Award | 148,000 | $2.03 |
| Sep 9, 2026 | Carr Douglas · officer: SVP Finance & Operations | Sale | 254 | $2.05 |
| Sep 9, 2026 | Pfeiffenberger Brent · director, officer: President and CEO | F-InKind | 463 | $2.11 |
| Sep 9, 2026 | Russotti Gregory · officer: See Remarks | Sale | 534 | $2.05 |
| Aug 18, 2026 | Pfeiffenberger Brent · director, officer: President and CEO | F-InKind | 31,172 | $1.92 |
| Aug 5, 2026 | Carr Douglas · officer: SVP Finance & Operations | Sale | 275 | $1.98 |
| Jun 15, 2026 | Russotti Gregory · officer: See Remarks | Sale | 2,584 | $2.23 |
| Jun 15, 2026 | Carr Douglas · officer: SVP Finance & Operations | Sale | 1,654 | $2.23 |
| Jun 15, 2026 | Pfeiffenberger Brent · director, officer: President and CEO | F-InKind | 13,849 | $2.24 |
| Jun 15, 2026 | Cowan Chad · officer: Chief Scientific Officer | F-InKind | 358 | $2.24 |
| Jun 12, 2026 | Murphy Martin Patrick · director | A-Award | 74,000 | $2.24 |
| Jun 12, 2026 | Blackwell Kimberly · director | A-Award | 74,000 | $2.24 |
| Jun 12, 2026 | Riva Alessandro · director | A-Award | 74,000 | $2.24 |
| Jun 12, 2026 | Quimi Daphne · director | A-Award | 74,000 | $2.24 |
| Jun 12, 2026 | Lee Han Myung · director | A-Award | 74,000 | $2.24 |
| Jun 9, 2026 | Carr Douglas · officer: SVP Finance & Operations | Sale | 249 | $2.11 |
| Jun 9, 2026 | Russotti Gregory · officer: See Remarks | Sale | 524 | $2.11 |
| Jun 9, 2026 | Pfeiffenberger Brent · director, officer: President and CEO | F-InKind | 463 | $2.13 |
| May 19, 2026 | Pfeiffenberger Brent · director, officer: President and CEO | F-InKind | 31,172 | $2.34 |
| May 6, 2026 | Carr Douglas · officer: SVP Finance & Operations | Sale | 264 | $2.34 |
| Apr 10, 2026 | Murphy Martin Patrick · director | A-Award | 88,000 | $0.59 |
| Apr 3, 2026 | Cowan Chad · officer: Chief Scientific Officer | F-InKind | 1,365 | $2.19 |
| Mar 16, 2026 | Carr Douglas · officer: SVP Finance & Operations | Sale | 7,043 | $2.55 |
| Mar 16, 2026 | Russotti Gregory · officer: See Remarks | Sale | 10,076 | $2.55 |
| Mar 13, 2026 | Pfeiffenberger Brent · director, officer: President and CEO | F-InKind | 55,397 | $2.73 |
| Mar 13, 2026 | Cowan Chad · officer: Chief Scientific Officer | F-InKind | 1,431 | $2.73 |
| Mar 11, 2026 | Russotti Gregory · officer: See Remarks | Sale | 479 | $2.54 |
Institutional positioning
13F filings over the trailing two quarters
New 69Increased 47Reduced 25Sold out 11
| Filer | Action | Shares | Filed |
|---|---|---|---|
| TCG CROSSOVER MANAGEMENT, LLC | New Position | 17,754,430 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | New Position | 17,754,430 | May 15, 2026 |
| TCG Crossover Management, LLC | Unchanged | 17,754,430 | Aug 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 17,754,430 | Aug 14, 2026 |
| Versant Venture Management, LLC | Unchanged | 12,166,109 | Aug 12, 2026 |
| VERSANT VENTURE MANAGEMENT, LLC | New Position | 12,166,109 | May 5, 2026 |
| DEEP TRACK CAPITAL, LP | New Position | 9,487,745 | May 15, 2026 |
| Deep Track Capital, LP | Reduced | 9,462,645 | Aug 14, 2026 |
| COMMODORE CAPITAL LP | New Position | 8,695,652 | May 15, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 8,695,652 | Aug 14, 2026 |
| Commodore Capital LP | Unchanged | 8,695,652 | Aug 14, 2026 |
| VR ADVISER, LLC | New Position | 8,695,652 | May 15, 2026 |
| VR Adviser, LLC | Unchanged | 8,695,652 | Aug 14, 2026 |
| RTW INVESTMENTS, LP | New Position | 8,695,652 | May 15, 2026 |
| BlackRock, Inc. | Increased | 8,091,768 | Aug 7, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 15, 2026